News & Updates

Adding pyrazinamide (PZA) to the initial tuberculosis (TB) treatment in older patients may lead to an increase in the incidence of adverse events (AEs), particularly allergic reactions, but not in-hospital mortality, length of hospital stay, or hepatotoxicity, reports a study, which used data from the Japanese Diagnosis Procedure Combination inpatient database.

Children born during the COVID-19 pandemic or to mothers with history of prenatal SARS-CoV-2 infection are not at increased risk of autism compared with their counterparts who were born before the pandemic or have no exposure to maternal SARS-CoV-2 infection, as reported in a cohort study.

Longer treatment with bulevirtide (BLV) monotherapy in patients with chronic hepatitis delta (CHD) for 96 weeks results in sustained or continued improvements in virologic, biochemical, and combined responses, a study has shown.

In a cohort study of over 18 million individuals with up to 2 years of follow-up, the incidences of most mental illnesses were markedly elevated following COVID-19 diagnosis compared with before or without COVID-19, particularly among the unvaccinated and before COVID-19 vaccines became available.

Pregnant and lactating women in Singapore generally have low acceptance of the COVID-19 vaccine due to safety concerns, reports a recent study.

The risk of developing acute kidney injury (AKI) is significantly higher in critically ill patients with influenza A than those with COVID-19, a study by researchers at the University of Hong Kong (HKU) has found.

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.